Cellectis SA (CLLS)
1.85
-0.01
(-0.54%)
USD |
NASDAQ |
Nov 22, 12:13
Cellectis Debt to Equity Ratio: 0.3579 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
September 30, 2024 | 0.3579 |
June 30, 2024 | 0.2995 |
March 31, 2024 | 0.4993 |
December 31, 2023 | 0.3968 |
September 30, 2023 | 0.4195 |
June 30, 2023 | 0.3464 |
March 31, 2023 | 0.1552 |
December 31, 2022 | 0.1572 |
September 30, 2022 | 0.1835 |
June 30, 2022 | 0.1141 |
March 31, 2022 | 0.1078 |
December 31, 2021 | 0.095 |
September 30, 2021 | 0.0903 |
June 30, 2021 | 0.0802 |
March 31, 2021 | 0.089 |
December 31, 2020 | 0.0853 |
September 30, 2020 | 0.0149 |
June 30, 2020 | 0.0216 |
March 31, 2020 | 0.00 |
December 31, 2019 | 0.00 |
Date | Value |
---|---|
September 30, 2019 | 0.00 |
June 30, 2019 | 0.00 |
March 31, 2019 | 0.00 |
December 31, 2018 | 0.00 |
September 30, 2018 | 0.0005 |
June 30, 2018 | 0.0017 |
March 31, 2018 | 0.00 |
December 31, 2017 | 0.00 |
September 30, 2017 | 0.00 |
June 30, 2017 | 0.0001 |
March 31, 2017 | 0.0014 |
December 31, 2016 | 0.0062 |
September 30, 2016 | 0.0074 |
June 30, 2016 | 0.0083 |
March 31, 2016 | 0.0075 |
December 31, 2015 | 0.007 |
September 30, 2015 | 0.0128 |
June 30, 2015 | 0.0118 |
March 31, 2015 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
0.4993
Maximum
Mar 2024
0.1757
Average
0.1109
Median
Debt to Equity Ratio Benchmarks
Edap TMS SA | 0.089 |
DBV Technologies SA | -- |
Genfit SA | 0.9462 |
Adaptimmune Therapeutics PLC | 0.6234 |
Akari Therapeutics PLC | -- |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 395.88M |
Total Liabilities (Quarterly) | 266.45M |
Shareholders Equity (Quarterly) | 129.42M |
Current Ratio | 1.777 |
Net Debt Paydown Yield | -1.21% |